Skip to content
Screener

Interest Expense at other companies

Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$1.43M-22.7%
Opko Health logo
Opko HealthOPK
$11.38M-83.8%
Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
$724+53.7%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$2.62M-27.1%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$2.81M+0.9%
Abbott logo
AbbottABT
$351M+190%

Segments

By segment

See full
Reportable Segment Aggregation Before Other Operating$15.1M-13.8%

Other financials

Income statement

See full
Revenue$74.3M+88.0%
Gross profit$59.2M+71.7%
Operating income-$4.0M+93.4%
Net income-$17.6M+76.8%
EPS (diluted)-$0.21+80.0%

Balance sheet

See full
Cash & equivalents$182.5M+22.0%
Total debt$167.1M-18.9%
Total equity-$344.3M+15.2%
Total assets$327.1M+30.7%

Cash flow

See full
Operating cash flow-$1.9M+96.9%
CapEx$44.0K-54.6%
Free cash flow-$2.0M+96.9%

Valuation

See full
Market cap$693.32M-4.9%
Enterprise value$677.96M-13.7%
P/S2.9×-3.5×

Profitability

See full
Gross margin82.9%-4.0pp
Operating margin-17%-8.2pp
Net margin-41.3%-19.1pp
FCF margin-15.4%-7.4pp

Returns & leverage

See full
Return on equity-147.9%
Debt / equity5.6×
Current ratio1.9×-0.5×

Where this comes from

Reported directly by Phathom Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.

The source filing: Phathom Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 7:05 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324867
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss from operations(3,965)(59,924)(19,442)(138,786)
Other (expense) income:
Interest income1,5101,7873,2464,427
Interest expense(15,103)(17,518)(30,900)(35,588)
Other expense, net(24)(155)(855)(179)
Total other expense(13,617)(15,886)(28,509)(31,340)
Net loss and comprehensive loss$(17,582)$(75,810)$(47,951)$(170,126)
Net loss per share, basic and diluted$(0.21)$(1.05)$(0.58)$(2.36)

Item 1. Financial Statements (unaudited)

FAQ

What is Phathom Pharmaceuticals, Inc.'s interest expense?
Phathom Pharmaceuticals, Inc. (PHAT) reported interest expense of $15.1M in Q2 2026.
How has Phathom Pharmaceuticals, Inc.'s interest expense changed year-over-year?
Phathom Pharmaceuticals, Inc.'s interest expense decreased by 13.8% year-over-year, from $17.52M to $15.1M.
What is the long-term trend for Phathom Pharmaceuticals, Inc.'s interest expense?
Over 4 years (2021 to 2025), Phathom Pharmaceuticals, Inc.'s interest expense has grown at a 78.0% compound annual growth rate (CAGR), from $6.79M to $68.12M.
What does interest expense mean?
Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.

Ask your AI about Phathom Pharmaceuticals, Inc.'s interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude